Karen Malateste
Overview
Explore the profile of Karen Malateste including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
407
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dahourou D, Tisseron C, Yonaba C, Djaha J, NGbeche M, Moh C, et al.
BMC Public Health
. 2025 Jan;
25(1):385.
PMID: 39885473
Background: Sexual and reproductive health issues in adolescents living with HIV (ALHIV) have been left behind in HIV care programs. ALHIV are at risk of unintended pregnancy which jeopardizes their...
2.
Desmonde S, Dame J, Malateste K, David A, Amorissani-Folquet M, NGbeche S, et al.
BMJ Glob Health
. 2025 Jan;
10(1.
PMID: 39809526
Introduction: We describe the 24-month incidence of Dolutegravir (DTG)-containing antiretroviral treatment (ART) initiation since its introduction in 2019 in West Africa. Methods: We included all patients aged 0-24 years on...
3.
Tiendrebeogo T, Malateste K, Poda A, Minga A, Lahiri C, Ezechi O, et al.
J Int AIDS Soc
. 2024 Nov;
27(12):e26371.
PMID: 39604062
Introduction: Adverse metabolic effects related to dolutegravir (DTG) are increasingly reported as countries are adopting DTG-based regimens as first-line antiretroviral therapy (ART), but there is limited data from sub-Saharan Africa....
4.
Desmonde S, Dame J, Malateste K, David A, Amorissani-Folquet M, NGbeche S, et al.
medRxiv
. 2024 Jun;
PMID: 38826257
Introduction: We describe the 24-month incidence of Dolutegravir (DTG)-containing antiretroviral treatment (ART) initiation since its introduction in 2019 in West Africa. Methods: We included all patients aged 0-24 years on...
5.
Tiendrebeogo T, Malateste K, Poda A, Minga A, Messou E, Chenal H, et al.
Open Forum Infect Dis
. 2024 Apr;
11(5):ofae139.
PMID: 38680609
Transition to dolutegravir among 21 167 individuals experienced in antiretroviral therapy in West Africa showed heterogeneous timelines and patterns. Initially reported sex disparities tended to catch up over time with...
6.
Ben Farhat J, Tiendrebeogo T, Malateste K, Poda A, Minga A, Messou E, et al.
J Acquir Immune Defic Syndr
. 2024 Mar;
96(2):114-120.
PMID: 38427928
Objectives: Efforts to control the COVID-19 pandemic have potentially compromised the availability and/or quality of HIV services. We aimed to assess the pandemic's impact on antiretroviral therapy (ART) initiation and...
7.
Lewis J, Stephens J, Musick B, Brown S, Malateste K, Ha Dao Ostinelli C, et al.
J Biomed Inform
. 2022 Jun;
131:104110.
PMID: 35680074
We describe the design, implementation, and impact of a data harmonization, data quality checking, and dynamic report generation application in an international observational HIV research network. The IeDEA Harmonist Data...
8.
Pressiat C, Dainguy E, Treluyer J, Yonaba C, Urien S, Eboua F, et al.
Antivir Ther
. 2022 Apr;
26(6-8):134-140.
PMID: 35485334
Background: Few pharmacokinetic data were reported on dispersible tablets despite their increasing use. One hundred fifty HIV-infected children receiving lamivudine were enrolled in the MONOD ANRS 12,206 trial. Three galenic...
9.
Justice A, Goetz M, Stewart C, Hogan B, Humes E, Luz P, et al.
Lancet HIV
. 2022 Feb;
9(4):e269-e280.
PMID: 35218732
Late presentation for care is a major impediment to the prevention and effective treatment of HIV infection. Older individuals are at increased risk of late presentation, represent a growing proportion...
10.
Jesson J, Ephoevi-Ga A, Ake-Assi M, Koumakpai S, NGbeche S, Dainguy E, et al.
BMC Nutr
. 2021 Dec;
7(1):83.
PMID: 34903301
Background: Nutritional care is not optimally integrated into pediatric HIV care in sub-Saharan Africa. We assessed the 6-month effect of a nutritional support provided to children living with HIV, followed...